Helicobacter pylori CAs inhibition.

Q3 Biochemistry, Genetics and Molecular Biology
Enzymes Pub Date : 2024-01-01 Epub Date: 2024-06-08 DOI:10.1016/bs.enz.2024.05.013
Bianca Laura Bernardoni, Concettina La Motta, Simone Carradori, Ilaria D'Agostino
{"title":"Helicobacter pylori CAs inhibition.","authors":"Bianca Laura Bernardoni, Concettina La Motta, Simone Carradori, Ilaria D'Agostino","doi":"10.1016/bs.enz.2024.05.013","DOIUrl":null,"url":null,"abstract":"<p><p>Infections from Helicobacter pylori (Hp) are endangering Public Health safety worldwide, due to the associated high risk of developing severe diseases, such as peptic ulcer, gastric cancer, diabetes, and cardiovascular diseases. Current therapies are becoming less effective due to the rise of (multi)drug-resistant phenotypes and an urgent need for new antibacterial agents with innovative mechanisms of action is pressing. Among the most promising pharmacological targets, Carbonic Anhydrases (EC: 4.2.1.1) from Hp, namely HpαCA and HpβCA, emerged for their high druggability and crucial role in the survival of the pathogen in the host. Thereby, in the last decades, the two isoenzymes were isolated and characterized offering the opportunity to profile their kinetics and test different series of inhibitors.</p>","PeriodicalId":39097,"journal":{"name":"Enzymes","volume":"55 ","pages":"213-241"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enzymes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.enz.2024.05.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Infections from Helicobacter pylori (Hp) are endangering Public Health safety worldwide, due to the associated high risk of developing severe diseases, such as peptic ulcer, gastric cancer, diabetes, and cardiovascular diseases. Current therapies are becoming less effective due to the rise of (multi)drug-resistant phenotypes and an urgent need for new antibacterial agents with innovative mechanisms of action is pressing. Among the most promising pharmacological targets, Carbonic Anhydrases (EC: 4.2.1.1) from Hp, namely HpαCA and HpβCA, emerged for their high druggability and crucial role in the survival of the pathogen in the host. Thereby, in the last decades, the two isoenzymes were isolated and characterized offering the opportunity to profile their kinetics and test different series of inhibitors.

幽门螺旋杆菌 CAs 抑制剂。
幽门螺旋杆菌(Hp)感染危及全球公共卫生安全,因为它极易引发严重疾病,如消化性溃疡、胃癌、糖尿病和心血管疾病。由于(多重)耐药性表型的增加,目前的疗法越来越不奏效,因此迫切需要具有创新作用机制的新型抗菌剂。在最有希望的药理靶点中,来自 Hp 的碳酸酐酶(EC:4.2.1.1),即 HpαCA 和 HpβCA,因其高可药性和在病原体在宿主体内生存的关键作用而崭露头角。因此,在过去的几十年中,这两种同工酶被分离出来并进行了表征,为研究它们的动力学和测试不同系列的抑制剂提供了机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Enzymes
Enzymes Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
4.30
自引率
0.00%
发文量
10
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信